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Introduction. Baseline neutrophil-to-lymphocyte ratio (NLR) has been repeatedly reported as a significant prognostic factor in
advanced cancer patients. We explored whether changes in NLR may predict outcome of advanced cancer patients enrolled into
phase 1 trials and treated with PD-1/PD-L1 inhibitors. Patients and Methods. Advanced cancer patients enrolled into phase 1 trials
between September 2013 andMay 2016 and treated with anti-PD-1/PD-L1 agents were included in this retrospective study. NLRwas
calculated at baseline and after 2 cycles of treatment. Royal Marsden Hospital (RMH) prognostic score and Eastern Cooperative
Group (ECOG) performance status (PS) were determined at baseline. Kaplan-Meier estimation and Cox regression analyses were
used to assess the impact of NLR dynamics on PFS. Results. Among the 55 patients eligible, 26 (47%) were treated with anti-PD-
L1 monotherapy, 22 (40%) received single agent anti-PD-1, and 7 (13%) were given a tyrosine kinase inhibitor (TKI) plus a PD-1
inhibitor. Neither ECOG PS nor RMH prognostic score was significantly associated with PFS in our cohort, whereas changes in
NLR significantly impacted on PFS. Conclusion. Changes in the NLRmay be a useful predicting factor in advanced cancer patients
treated with anti-PD-1/PD-L1 agents. Further prospective trials are needed to verify these findings.
1. Introduction
Immune checkpoint inhibitors have emerged as potent and
effective treatments for various types of haematological and
solid malignancies [1]. In particular, blockade of the PD-
1/PD-L1 axis can result in dramatic and sustained tumour
regression in multiple cancer types [2, 3]. Under normal
circumstances, this pathway is necessary tomaintain immune
homeostasis [4]. When PD-L1 binds to PD-1, an inhibitory
signal is transmitted into the T-cell, protecting normal cells
from collateral damage. Nevertheless, upregulation of PD-
L1 may allow cancer cells to evade immune surveillance
[3]. Considering the costs and potential side effects of novel
anti-PD-1/PD-L1 agents, it is of vital importance to identify
reliable biomarkers to select the most suitable patients for
these drugs while sparing nonresponders from toxicity.
PD-L1 expression as determined by immunohistochem-
istry is considered the most useful biomarker in predicting
outcomes of PD-1/PD-L1 blockade [4]. Several studies have
investigated the role of PD-L1 expression in tumour and
stromal cells as a potential biomarker of response, but the
results were somewhat contradictory [4, 5]. Indeed, several
factors can limit the reliability of this biomarker, including
the use of different monoclonal antibodies for detection of
PD-L1, variable procedures for biopsy collection and storage,
lack of defined thresholds to describe PD-L1 expression in
samples, and intratumour heterogeneity in PD-L1 expres-
sion [5] The presence of microsatellite instability, tumour
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mutational load, tumour-infiltrating lymphocytes (TILs),
myeloid-derived suppressor cells (MDSCs), indoleamine 2,3-
dioxygenase, regulatory T cells, and immune specific signa-
tures have been also investigated with promising results [6–
8]. Despite the aforementioned methods, there is still a lack
of a simple, effective, and definitive biomarker of response to
immune checkpoint inhibitors.
Increased neutrophil-to-lymphocyte ratio (NLR) has
been reported as an independent poor prognostic indicator
in several malignancies and its normalisation following
treatment has been found to predict survival in cancer
patients considered for early phase clinical trials [9]. Here,
we investigated the usefulness of NRL changes in predict-
ing progression-free survival (PFS) in patients undergoing
treatment with PD-1/PD-L1 inhibitors within phase 1 clinical
trials.
2. Patients and Methods
Data of metastatic cancer patients enrolled in phase 1 trials
between September 2013 andMay 2016 in our institutionwere
retrospectively reviewed. Patients treated with PD-1/PD-L1
checkpoint-directed therapy were eligible. All the subjects
had a histologically confirmed diagnosis of metastatic solid
cancer and were intended to receive treatment with an anti-
PD-1/PD-L1 agent given as monotherapy or in combination
with a tyrosine kinase inhibitor (TKI). Baseline parameters,
tumour characteristics, and treatment data were all reviewed
and anonymously collected for this study. All the subjects
met the standard inclusion criteria for phase 1 trials: Eastern
Cooperative Group (ECOG) performance status (PS) 0 or 1;
measurable disease based on Response Evaluation Criteria in
Solid Tumour (RECIST); adequate bone marrow, liver, and
kidney function; life expectancy of at least 3 months. Baseline
characteristics recorded in the eligible population included
demographic variables, tumour type, anticancer treatment
(anti-PD-1 versus anti-PD-L1 versus anti-PD-L1 plus TKI),
number of previous lines for metastatic disease, Royal Mars-
den Hospital (RMH) prognostic score [10], white blood
cell (WBC) level, absolute neutrophil count (ANC), abso-
lute lymphocyte count (ALC), and neutrophil-to-lymphocyte
ratio (NLR). The RMH prognostic score (range 0–3) was
calculated at baseline, taking into account albumin level,
lactate dehydrogenase (LDH) level, and number ofmetastatic
sites [10].TheNLRwas calculated using the standard formula:
NLR = ANC/ALC. NLR was calculated at baseline (cycle 1
day 1), and after 6 weeks (2 cycles) of treatment. Patients
were treated until disease progression, death, or unacceptable
toxicity. We considered PFS as our main outcome, which was
defined as the time from treatment start until progression or
death, whichever occurred first.
To investigate the dynamics in NLR between baseline
and after 2 cycles of anti-PD-1/PD-L1 therapy, we used a
landmark approach by excluding patients who were not able
to receive at least 2 cycles of treatment to avoid guarantee
time bias. We used multivariate Cox regression analyses with
the relative NLR difference as independent and PFS as the
dependent variable. To adjust for possible confounding, we
Table 1: Patients’ characteristics at baseline. NCSLC = non-small
cell lung cancer; ECOG PS = Eastern Cooperative Oncology Group
performance status; GI = gastrointestinal; TKI = tyrosine kinase











Upper GI cancer 11 (20)
Bladder cancer 8 (15)
Renal cell carcinoma 8 (15)
Breast cancer 7 (13)
Colorectal cancer 2 (4)












Number of metastatic sites 2 (1–4)
Number of previous treatment lines 1 (1–6)
introduced the RMH score into the model and addition-
ally added a random effect for tumour entity, in order to
account for possible heterogeneity between tumour types.
We calculated univariate andmultivariate hazard ratios (HR)
with accompanied 95% confidence intervals (CI); however,
the multivariable analysis is considered as main analysis.
To visualize the prognostic effect of the NLR difference,
we created Kaplan-Meier plots. All 𝑝 values are exploratory
in nature with a conventional level of significance at 0.05.
All analyses were done using the statistical software R
(https://www.r-project.org/) and STATA (version 14).
3. Results
A total of 67 potentially eligible patients were identified.
Of those, 12 subjects received less than 2 cycles and were
therefore excluded from the analysis. The characteristics of
the included 55 patients are summarised in Table 1. Median
age of patients included was 61 years (40 to 80 years).
The most represented tumour type was non-small cell lung
cancer (NSCLC) with 18 (33%) subjects, followed by upper
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Table 2: Distribution of patient population in two groups. Group
A: neutrophil-to-lymphocyte ratio (NLR) after 2 cycles ≤ median
baseline NLR. Group B: NLR after 2 cycles >median baseline NLR.
ECOG PS = Eastern Cooperative Oncology Group performance
status; RMH = Royal Marsden Hospital; ANC = absolute neutrophil
count; ALC = absolute lymphocyte count; SD = standard deviation;
IQR = interquartile range; NLR = neutrophil-to-lymphocyte ratio.




Female 11 (39) 8 (30)
Male 17 (61) 19 (70)
ECOG PS 𝑛 (%)
0 16 (43) 20 (74)
1 12 (57) 7 (26)
RMH prognostic score 𝑛 (%)
0-1 25 (89) 25 (93)
2-3 3 (11) 2 (7)
Intervention 𝑛 (%)
Anti-PD-1 14 (50) 8 (30)
Anti-PD-L1 9 (32) 17 (63)
Anti-PD-1 plus TKI 5 (18) 2 (7)
Baseline ANC
Mean (SD) 5.1 (1.8) 4.1 (1.4)
Baseline ALC
Mean (SD) 1.3 (0.6) 1.3 (0.5)
Baseline NLR
Median (IQR) 3.9 (2.7–5.6) 3.0 (2.5–4.8)
ANC after 2 cycles
Median (IQR) 3.7 (2.8–5.1) 4.5 (3.5–5.7)
ALC after 2 cycles
Mean (SD) 1.4 (0.5) 1.2 (0.5)
NLR after 2 cycles
Median (IQR) 2.9 (2.2–3.7) 3.9 (2.8–7)
gastrointestinal (𝑛 = 10; 18%), bladder (𝑛 = 8; 15%), and
breast (𝑛 = 7; 13%) carcinomas. Median number of previous
lines of treatment for metastatic disease was 1 (range 1–6)
while baseline median number of metastatic sites of disease
was 2 (range 1–4). RMH prognostic score at baseline was 0
in 31 (56%) subjects and 1 or higher in 24 (64%) subjects.
Proportion of patients with ECOGPS 0 or 1 was 36 (65%) and
19 (35%), respectively. In total, 26 (47%) of the patients were
treated with anti-PD-L1 monotherapy, 22 (40%) received
single agent anti-PD-1, and 7 (13%) were given a TKI in
combination with a PD-1 inhibitor.
Onunivariate analysis, baselineNLR, treatmentmodality,
RMH score, ECOG PS, and number of metastatic sites did
not have significant impact on PFS. Baseline median NLR
was 3.4 in the overall population. Patient population was
divided into 2 distinct groups based on decrease (GroupA) or
increase (Group B) of NLR in comparison with median NLR
after treatment with a PD-1/PD-L1 inhibitor. No substantial
differences in distribution were observed between these 2
groups in terms of age, sex, type of treatment, ECOG PS,
and RMH prognostic score (Table 2). Increased NLR after 2
cycles of anti-PD-1/PD-L1 therapy had a negative effect on
PFS (HR 1.14, 95% CI 1.06–1.23, 𝑝 = 0.004), (Figure 1).
This effect was also observed in our multivariate analysis,
Progression-free survival by median NLR dierence
Below or equal to median NLR (N = 28)
Above median NLR (N = 27)
log-rank test p = 0.004
200 400 600 8000














Figure 1: Progression-free survival (PFS) stratified by median dif-
ferences in neutrophil-to-lymphocyte ratio (NLR) between baseline
and after 2 doses of treatment with an anti-PD-1/PD-L1 inhibitor,
showing longer PFS in patients with a reduction of NLR compared
to the median baseline NLR.
where increased NLR was associated with decreased PFS
after adjusting for RMH prognostic score (HR 1.03, 95%
CI 1.01–1.04, 𝑝 < 0.001). Baseline median ANC level was
significantly higher in Group A than in Group B (𝑝 = 0.029).
In Group A, a reduction in median ANC was shown after 2
cycles of treatment when compared with baseline ANC level,
whereas this was not observed in Group B. After 2 cycles
of treatment with anti-PD-1/PD-L1 agent, median ANC was
significantly higher in Group B when compared to Group A
(𝑝 = 0.014). Median ALC did not change significantly after
treatment (𝑝 = 0.222) and no significant differences were
shown between baseline and posttreatment values in both
Group A and Group B (𝑝 = 0.24) (Table 2).
4. Discussion
Molecular selection in patients undergoing treatment with
immune checkpoint inhibitors is an urgent unmet medical
need. Ongoing approval of several anti-PD-1/PD-L1 agents
and the emergence of safety concerns from immune-related
adverse events also highlight the need for biomolecular strat-
ification. Several biomarkers have been investigated, some
of which have shown potential usefulness in predicting the
activity of these agents. So far, PD-L1 expression in tumour
cells remains the most reliable but many technical limitations
have been associated with this biomarker [4, 5]. Furthermore,
individuals with negative PD-L1 expression can still respond
to PD-1/PD-L1 blockade, further questioning the value of
PD-L1 expression as a universal biomarker [11]. Therefore,
alternative markers of response need to be identified.
Clinicopathologic factors have been extensively inves-
tigated in several tumour types and anticancer therapies.
Among them, ECOG PS has been repeatedly reported as a
strong predictor of survival in multiple settings. The RMH
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prognostic score was electively implemented in advanced
cancer patients enrolled in phase 1 studies [10]. Unexpect-
edly, neither ECOG PS nor RMH prognostic score were
significantly associated with PFS in our cohort. Our results
are not consistent with previous studies showing significant
prognostic significance of RMH score and ECOGPS in phase
1 trial patients [10, 12, 13].
Baseline NLR has been reported to predict overall
survival in cancer patients undergoing both conventional
chemotherapy and targeted treatments, including immune
checkpoint inhibitors. In previous reports, a correlation
between baseline NLR and survival was shown in kidney
cancer and NSCLC treated with IL-2 and nivolumab, respec-
tively [14, 15]. Conversely, in our group of patients, baseline
NLRwas not found to correlate with PFS, although this result
may have been determined by the limited sample size. In our
study, we retrospectively analysed phase 1 trial cancer patients
with advanced disease who had received at least 2 cycles of
treatment with anti-PD-1/PD-L1 agent, to assess the signif-
icance of NLR as an independent biomarker in predicting
clinical benefit in terms of PFS. Interestingly, a decrease in
NLR after 2 cycles of treatment with PD-1/PD-L1 blockade
was associated with longer PFS in our cohort. Accordingly,
changes in NLR had shown to predict better outcomes in
cancer patients undergoing conventional chemotherapy or
targeted treatment but had beennever investigated in subjects
receiving immune checkpoint inhibitors [16–18].
Another important finding in this study was the obser-
vation that negative or positive changes in NLR were driven
by a decrease in ANC and not by changes in ALC as
one would have expected. Though retrospective in nature,
our findings on ANC may be interpreted as hypothesis-
generating. Despite the fact the T lymphocyte activity is
the main target of PD-1/PD-L1 blockade, our results may
suggest an important interaction between the neutrophils and
tumour microenvironment. We may also speculate that the
systemic effect of anti-PD-1/PD-L1 agents involves a crucial
effect on circulating myeloid populations included in the
ANCasmeasured by automated full blood cell count analyser.
Preclinical evidence shows that MDSCs can impair the effi-
cacy of immunotherapy [19]. Under physiological conditions,
there is a low level of MDSCs in the bloodstream while these
populations rapidly expand during immunological responses
to infections, inflammation, and cancer [20]. MDSCs can
adopt multiple mechanisms to induce immunosuppression,
including production of arginase 1 and inducible nitric oxide
synthase, leading to T-cell inhibition [19, 20].MDSCs are also
known to enhance cancer cell proliferation, confer resistance
to anticancer therapies, and promote angiogenesis andmetas-
tasis [20]. Concomitant targeting of MDSCs may therefore
increase the antitumour activity of PD-1/PD-L1 inhibitors
in nonresponders. Moreover, a decreased mobilisation of
MDSCs from the bone marrow may represent a systemic
effect of anti-PD-1/PD-L1 treatment that needs to be better
investigated in preclinical studies. A subsequent decrease of
tumour-infiltrating MDSCs may then unleash antitumour
activity of TILs and ultimately contribute to the therapeutic
effect of anti-PD-1/PD-L1 agents.
Our study has several biases, including its retrospective
nature, limited sample size, heterogeneous tumour types, and
the choice of PFS as endpoint instead of overall survival.
Nevertheless, we showed that NLR, a simple haematological
parameter easily obtainable in daily clinical practice, may be
used to predict clinical benefit from PD-1/PD-L1 inhibitors.
These results are in line with common clinical experience
with these agents, where a rapid clinical benefit can be
observed despite unusual initial patterns of imaging response.
Further studies conducted in larger prospective cohorts
of patients undergoing treatment with immune checkpoint
inhibitors are needed to confirm the predictive role of NLR
in this setting.
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